Teaching an old dog new tricks: The case of Fenbendazole
•Fenbendazole has similar mechanism of action to some anticancer drugs.•Qualitative and quantitative analysis of formulated fenbendazole indicates some formulation issues that hinder distribution.•Fenbendazole exhibits cytotoxic effect against human cancer cell lines. The objective of this study is...
Saved in:
| Published in | Cancer treatment and research communications Vol. 32; p. 100601 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Elsevier Ltd
2022
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2468-2942 2468-2942 |
| DOI | 10.1016/j.ctarc.2022.100601 |
Cover
| Abstract | •Fenbendazole has similar mechanism of action to some anticancer drugs.•Qualitative and quantitative analysis of formulated fenbendazole indicates some formulation issues that hinder distribution.•Fenbendazole exhibits cytotoxic effect against human cancer cell lines.
The objective of this study is the assessment of the cytotoxic effect of fenbendazole and its commercially available formulation, which is used for its antihelmintic properties. The formulation was tested for its efficacy as well as the determination of the ingredients with proliferation assays and analytical techniques. HPLC, LC-MS and NMR confirmed the stated amount of active ingredient on the label. Dissolution studies were performed to simulate the ability of fenbendazole to dissolve adequately in the fluids of the Gastrointestinal tract, be absorbed in the circulation and reach certain areas of the human body. However, dissolution studies showed that both brands possess issues in their distribution. The in vitro drug screening exhibited potential cytotoxic effect in different types of human cancer cell lines and MDA-MB-231 human breast adenocarcinoma cells appeared to be the most sensitive with IC50 value lower than 10 μM. |
|---|---|
| AbstractList | Highlights•Fenbendazole has similar mechanism of action to some anticancer drugs. •Qualitative and quantitative analysis of formulated fenbendazole indicates some formulation issues that hinder distribution. •Fenbendazole exhibits cytotoxic effect against human cancer cell lines. The objective of this study is the assessment of the cytotoxic effect of fenbendazole and its commercially available formulation, which is used for its antihelmintic properties. The formulation was tested for its efficacy as well as the determination of the ingredients with proliferation assays and analytical techniques. HPLC, LC-MS and NMR confirmed the stated amount of active ingredient on the label. Dissolution studies were performed to simulate the ability of fenbendazole to dissolve adequately in the fluids of the Gastrointestinal tract, be absorbed in the circulation and reach certain areas of the human body. However, dissolution studies showed that both brands possess issues in their distribution. The in vitro drug screening exhibited potential cytotoxic effect in different types of human cancer cell lines and MDA-MB-231 human breast adenocarcinoma cells appeared to be the most sensitive with IC50 value lower than 10 μM.The objective of this study is the assessment of the cytotoxic effect of fenbendazole and its commercially available formulation, which is used for its antihelmintic properties. The formulation was tested for its efficacy as well as the determination of the ingredients with proliferation assays and analytical techniques. HPLC, LC-MS and NMR confirmed the stated amount of active ingredient on the label. Dissolution studies were performed to simulate the ability of fenbendazole to dissolve adequately in the fluids of the Gastrointestinal tract, be absorbed in the circulation and reach certain areas of the human body. However, dissolution studies showed that both brands possess issues in their distribution. The in vitro drug screening exhibited potential cytotoxic effect in different types of human cancer cell lines and MDA-MB-231 human breast adenocarcinoma cells appeared to be the most sensitive with IC50 value lower than 10 μM. •Fenbendazole has similar mechanism of action to some anticancer drugs.•Qualitative and quantitative analysis of formulated fenbendazole indicates some formulation issues that hinder distribution.•Fenbendazole exhibits cytotoxic effect against human cancer cell lines. The objective of this study is the assessment of the cytotoxic effect of fenbendazole and its commercially available formulation, which is used for its antihelmintic properties. The formulation was tested for its efficacy as well as the determination of the ingredients with proliferation assays and analytical techniques. HPLC, LC-MS and NMR confirmed the stated amount of active ingredient on the label. Dissolution studies were performed to simulate the ability of fenbendazole to dissolve adequately in the fluids of the Gastrointestinal tract, be absorbed in the circulation and reach certain areas of the human body. However, dissolution studies showed that both brands possess issues in their distribution. The in vitro drug screening exhibited potential cytotoxic effect in different types of human cancer cell lines and MDA-MB-231 human breast adenocarcinoma cells appeared to be the most sensitive with IC50 value lower than 10 μM. The objective of this study is the assessment of the cytotoxic effect of fenbendazole and its commercially available formulation, which is used for its antihelmintic properties. The formulation was tested for its efficacy as well as the determination of the ingredients with proliferation assays and analytical techniques. HPLC, LC-MS and NMR confirmed the stated amount of active ingredient on the label. Dissolution studies were performed to simulate the ability of fenbendazole to dissolve adequately in the fluids of the Gastrointestinal tract, be absorbed in the circulation and reach certain areas of the human body. However, dissolution studies showed that both brands possess issues in their distribution. The in vitro drug screening exhibited potential cytotoxic effect in different types of human cancer cell lines and MDA-MB-231 human breast adenocarcinoma cells appeared to be the most sensitive with IC50 value lower than 10 μM. |
| ArticleNumber | 100601 |
| Author | Parsonidis, Panagiotis Bouris, Ioannis Vlachou, Ioanna Mamagkaki, Alexandra Papasotiriou, Ioannis |
| Author_xml | – sequence: 1 givenname: Ioanna surname: Vlachou fullname: Vlachou, Ioanna organization: Research Genetic Cancer Centre S.A., Industrial Area of Florina 53100, Greece – sequence: 2 givenname: Panagiotis surname: Parsonidis fullname: Parsonidis, Panagiotis organization: Research Genetic Cancer Centre S.A., Industrial Area of Florina 53100, Greece – sequence: 3 givenname: Alexandra surname: Mamagkaki fullname: Mamagkaki, Alexandra organization: Research Genetic Cancer Centre S.A., Industrial Area of Florina 53100, Greece – sequence: 4 givenname: Ioannis surname: Bouris fullname: Bouris, Ioannis organization: Research Genetic Cancer Centre S.A., Industrial Area of Florina 53100, Greece – sequence: 5 givenname: Ioannis orcidid: 0000-0002-6145-946X surname: Papasotiriou fullname: Papasotiriou, Ioannis email: papasotiriou.ioannis@rgcc-international.com organization: Research Genetic Cancer Centre International GmbH Headquarters, Baarerstrasse 95, Zug 6300, Switzerland |
| BookMark | eNqNklFrFDEQx4NUsJ79BL7soy93JtlsNqsoSLG1UPDB8znMzc5es02TM9mznJ--u10RKcj5lDDM7z_wm3nJTkIMxNhrwVeCC_22X-EACVeSSzlWuObiGTuVSpulbJQ8-ev_gp3l3HPOhZGiVs0pM2sCvHFhW0Aoom-LNm6LQPfFkBze5nfF-oYKhExF7IoLChsKLfyKnl6x5x34TGe_3wX7fvF5ff5lef318ur80_USq0oNy7YjA6JVoFAKlK2oVFNyXZZUllpAZ4wWjWlKg4qQSgMtLytViwrAyJpEuWBXc24bobe75O4gHWwEZx8LMW0tpMGhJ4tC6Lo1itc1qUrUzUZvQEmDG6xlMwYvmJqz9mEHh3vw_k-g4HaSaXv7KNNOMu0sc8TezNguxR97yoO9cxnJewgU99lKbSquuDZqbC3nVkwx50Tdfw5onlDoBhhcDEMC54-wH2aWxiX8dJRsRkcBqXWJcBgtuSP8xyc8ehccgr-lA-U-7lMY92uFzdJy-226pemUpBzPqBGT1Pf_Djg6_gGxStaU |
| CitedBy_id | crossref_primary_10_1080_00498254_2022_2160676 crossref_primary_10_1039_D2CE01644C |
| Cites_doi | 10.1016/j.bmc.2012.09.013 10.1016/j.ejmech.2014.11.053 10.1007/s00044-010-9533-9 10.1016/0006-2952(84)90515-X 10.1007/BF02510042 10.1182/blood-2009-09-243055 10.1016/j.semcancer.2020.04.006 10.1038/s41523-019-0108-8 10.1093/neuonc/nor077 10.5772/intechopen.85229 10.1080/00034983.1984.11811787 10.2174/1389557053544047 10.1016/S1090-0233(05)80005-X 10.1016/0020-7519(88)90175-0 10.1111/j.1365-2885.1990.tb00773.x |
| ContentType | Journal Article |
| Copyright | 2022 The Author(s) The Author(s) Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. |
| Copyright_xml | – notice: 2022 The Author(s) – notice: The Author(s) – notice: Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION 7X8 ADTOC UNPAY DOA |
| DOI | 10.1016/j.ctarc.2022.100601 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2468-2942 |
| EndPage | 100601 |
| ExternalDocumentID | oai_doaj_org_article_c1167d84077e45179b6ba428cbc729d0 10.1016/j.ctarc.2022.100601 10_1016_j_ctarc_2022_100601 S2468294222000910 1_s2_0_S2468294222000910 |
| GroupedDBID | --M .1- .FO 0R~ 1P~ 4G. 53G 7-5 AAEDT AAEDW AAKOC AALRI AAOAW AATTM AAXKI AAXUO AAYWO ABMAC ABMZM ACDAQ ACGFS ACIEU ACLOT ACRLP ACVFH ADBBV ADCNI ADVLN AEBSH AEIPS AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGUBO AIEXJ AIGII AIIUN AIKHN AITUG AJUYK AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKOJK BLXMC BNPGV EBS EFJIC EFKBS EFLBG EJD FDB FIRID FYGXN GROUPED_DOAJ KOM M~E O9- OAUVE OC~ OK1 OO- ROL SSH SSZ T5K Z5R ~G- AACTN AFKWA AJOXV AMFUW NCXOZ 6I. AAFTH AAIAV ABLVK ABYKQ AJBFU AAYXX CITATION 7X8 ADTOC AGCQF UNPAY |
| ID | FETCH-LOGICAL-c554t-dfe8a1d4a4c21c2d154930633e3361af886198938c4ece38ad0354715aa827e13 |
| IEDL.DBID | UNPAY |
| ISSN | 2468-2942 |
| IngestDate | Fri Oct 03 12:43:17 EDT 2025 Tue Aug 19 21:49:07 EDT 2025 Sun Sep 28 06:33:46 EDT 2025 Thu Apr 24 22:52:37 EDT 2025 Wed Oct 01 02:45:23 EDT 2025 Fri Feb 23 02:42:05 EST 2024 Tue Feb 25 19:54:33 EST 2025 Tue Oct 14 19:29:31 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Fenbendazole Cytotoxicity Analysis Cancer |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. cc-by-nc-nd |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c554t-dfe8a1d4a4c21c2d154930633e3361af886198938c4ece38ad0354715aa827e13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-6145-946X |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://doi.org/10.1016/j.ctarc.2022.100601 |
| PQID | 2685040684 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_c1167d84077e45179b6ba428cbc729d0 unpaywall_primary_10_1016_j_ctarc_2022_100601 proquest_miscellaneous_2685040684 crossref_primary_10_1016_j_ctarc_2022_100601 crossref_citationtrail_10_1016_j_ctarc_2022_100601 elsevier_sciencedirect_doi_10_1016_j_ctarc_2022_100601 elsevier_clinicalkeyesjournals_1_s2_0_S2468294222000910 elsevier_clinicalkey_doi_10_1016_j_ctarc_2022_100601 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022 2022-00-00 20220101 2022-01-01 |
| PublicationDateYYYYMMDD | 2022-01-01 |
| PublicationDate_xml | – year: 2022 text: 2022 |
| PublicationDecade | 2020 |
| PublicationTitle | Cancer treatment and research communications |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
| References | Spagnuolo, Hu, Hurren, Wang, Gronda, Sukhai, Di Meo, Boss, Ashall, Zavareh, Fine, Simpson, Sharmeen, Rottapel, Schimmer (bib0014) 2009; 115 Rossignol, Maisonneuve (bib0004) 1984; 78 Kantharaju Kamanna (August 13th 2019). Synthesis and Pharmacological Profile of Benzimidazoles, Chemistry and Applications of Benzimidazole and its Derivatives, Maria Marinescu, IntechOpen, 10.5772/intechopen.85229. Available from Boiani, Gonzalez (bib0006) 2005; 5 Patil, Ganguly, Surana (bib0005) 2008; 1 Geeta, Swastika (bib0009) 2015; 97 Dawson, Gutteridge, Gull (bib0012) 1984; 33 Spasov, Yozhitsa, Bugaeva, Anisimova (bib0003) 1999; 33 Gao, Dang, Watson (bib0017) 2008; 47 Theodossiou, Ali, Grigalavicius (bib0021) 2019; 5 Tannock, Hill, Bristow, Harrington (bib0015) 2004 Narasimhan, Sharma, Kumar (bib0007) 2012; 21 Bai, Staedtke, Aprhys, Gallia, Riggins (bib0016) 2011; 13 . McKellar, Scott (bib0002) 1990; 13 Chung I., Barrows C., Wilson A., Rummel N., Badaruddin S., Mizokami A., Banyard J. and Zetter B.: Benzimidazole as novel therapeutic agent for metastatic prostate cancer. Poster session presented at the Annual Meeting of the American Association for Cancer Research, Washington DC, April 17-21, 2010. Martin (bib0011) 1997; 154 Yogita, Om (bib0010) 2012; 20 USP Dissolution, Stage 6 Harmonization, 2011. Sivakumar, Pradeepchandran, Jayaveera, Kumarnallasivan, Vijaianand, Venkatnarayanan (bib0008) 2011; 3 Kirtonia, Gala, Fernandes, Pandya, Pandey, Sethi, Khattar, Garg (bib0019) 2021; 68 Lacey (bib0013) 1988; 7 Rossignol (10.1016/j.ctarc.2022.100601_bib0004) 1984; 78 Gao (10.1016/j.ctarc.2022.100601_bib0017) 2008; 47 Geeta (10.1016/j.ctarc.2022.100601_bib0009) 2015; 97 Tannock (10.1016/j.ctarc.2022.100601_bib0015) 2004 Spasov (10.1016/j.ctarc.2022.100601_bib0003) 1999; 33 Patil (10.1016/j.ctarc.2022.100601_bib0005) 2008; 1 Martin (10.1016/j.ctarc.2022.100601_bib0011) 1997; 154 Spagnuolo (10.1016/j.ctarc.2022.100601_bib0014) 2009; 115 Kirtonia (10.1016/j.ctarc.2022.100601_bib0019) 2021; 68 10.1016/j.ctarc.2022.100601_bib0001 Dawson (10.1016/j.ctarc.2022.100601_bib0012) 1984; 33 Narasimhan (10.1016/j.ctarc.2022.100601_bib0007) 2012; 21 Theodossiou (10.1016/j.ctarc.2022.100601_bib0021) 2019; 5 Yogita (10.1016/j.ctarc.2022.100601_bib0010) 2012; 20 10.1016/j.ctarc.2022.100601_bib0020 Sivakumar (10.1016/j.ctarc.2022.100601_bib0008) 2011; 3 Bai (10.1016/j.ctarc.2022.100601_bib0016) 2011; 13 10.1016/j.ctarc.2022.100601_bib0018 Boiani (10.1016/j.ctarc.2022.100601_bib0006) 2005; 5 Lacey (10.1016/j.ctarc.2022.100601_bib0013) 1988; 7 McKellar (10.1016/j.ctarc.2022.100601_bib0002) 1990; 13 |
| References_xml | – year: 2004 ident: bib0015 article-title: The Basic Science of Oncology – volume: 1 start-page: 447 year: 2008 end-page: 460 ident: bib0005 article-title: A systematic review of benzimidazole derivatives as an antiulcer agent publication-title: Rasayan J. Chem. – volume: 33 start-page: 232 year: 1999 end-page: 243 ident: bib0003 article-title: Benzimidazole derivatives: spectrum of pharmacological activity and toxicological properties (a review) publication-title: Pharm. Chem. J. – volume: 68 start-page: 258 year: 2021 end-page: 278 ident: bib0019 article-title: Repurposing of drugs: an attractive pharmacological strategy for cancer therapeutics publication-title: Semin. Cancer Biol. – volume: 78 start-page: 135 year: 1984 end-page: 144 ident: bib0004 article-title: Benzimidazoles in the treatment of trichuriasis: a review publication-title: Ann. Trop. Med. Parasitol – reference: Chung I., Barrows C., Wilson A., Rummel N., Badaruddin S., Mizokami A., Banyard J. and Zetter B.: Benzimidazole as novel therapeutic agent for metastatic prostate cancer. Poster session presented at the Annual Meeting of the American Association for Cancer Research, Washington DC, April 17-21, 2010. – volume: 115 start-page: 4824 year: 2009 end-page: 4833 ident: bib0014 article-title: The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma publication-title: Blood – volume: 5 start-page: 13 year: 2019 ident: bib0021 article-title: Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT–tamoxifen hybrid therapy publication-title: npj Breast Cancer – volume: 21 start-page: 269 year: 2012 end-page: 283 ident: bib0007 article-title: Benzimidazole: a medicinally important heterocyclic moiety publication-title: Med. Chem. Res. – volume: 7 start-page: 885 year: 1988 end-page: 936 ident: bib0013 article-title: The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles publication-title: Int. J. Paracytol. – volume: 20 start-page: 6208 year: 2012 end-page: 6236 ident: bib0010 article-title: The therapeutic journey of benzimidazoles: a review publication-title: Bioorg. Med. Chem. – reference: . – volume: 13 year: 2011 ident: bib0016 article-title: Antiparasitic mebendazole shows survival benefit in two preclinical models of glioblastoma multiforme publication-title: Neuro. Oncol. – volume: 5 start-page: 409 year: 2005 end-page: 424 ident: bib0006 article-title: Imidazole and benzimidazole derivatives as chemotherapeutic agents publication-title: Mini. Rev. Med. Chem – volume: 3 start-page: 19 year: 2011 end-page: 31 ident: bib0008 article-title: Benzimidazole: an attractive pharmacophore in medicinal chemistry publication-title: Int. J. Pharm. Res – reference: USP <711>Dissolution, Stage 6 Harmonization, 2011. – volume: 13 start-page: 223 year: 1990 end-page: 247 ident: bib0002 article-title: The benzimidazole anthelmintic agents—A review publication-title: J. Vet. Pharmacol. Ther. – volume: 33 start-page: 1069 year: 1984 end-page: 1074 ident: bib0012 article-title: A comparison of the interaction of antihelminth benzimidazoles with tubulin isolated from mammalian tissue and the parasitic nematode Ascaridia galli publication-title: Biochem. Pharm. – volume: 97 start-page: 419 year: 2015 end-page: 443 ident: bib0009 article-title: Structure activity relationship (SAR) study of benzimidazole scaffold for different biological activities: a mini-review publication-title: Eur. J. Med. Chem – reference: Kantharaju Kamanna (August 13th 2019). Synthesis and Pharmacological Profile of Benzimidazoles, Chemistry and Applications of Benzimidazole and its Derivatives, Maria Marinescu, IntechOpen, 10.5772/intechopen.85229. Available from: – volume: 154 start-page: 11 year: 1997 end-page: 34 ident: bib0011 article-title: Review: modes of Action of Anthelmintic Drugs publication-title: Vet. J – volume: 47 start-page: 37 year: 2008 end-page: 40 ident: bib0017 article-title: Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins publication-title: J. Am. Assoc. Lab Anim. Sci. – volume: 20 start-page: 6208 year: 2012 ident: 10.1016/j.ctarc.2022.100601_bib0010 article-title: The therapeutic journey of benzimidazoles: a review publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2012.09.013 – volume: 1 start-page: 447 year: 2008 ident: 10.1016/j.ctarc.2022.100601_bib0005 article-title: A systematic review of benzimidazole derivatives as an antiulcer agent publication-title: Rasayan J. Chem. – volume: 3 start-page: 19 year: 2011 ident: 10.1016/j.ctarc.2022.100601_bib0008 article-title: Benzimidazole: an attractive pharmacophore in medicinal chemistry publication-title: Int. J. Pharm. Res – volume: 97 start-page: 419 year: 2015 ident: 10.1016/j.ctarc.2022.100601_bib0009 article-title: Structure activity relationship (SAR) study of benzimidazole scaffold for different biological activities: a mini-review publication-title: Eur. J. Med. Chem doi: 10.1016/j.ejmech.2014.11.053 – year: 2004 ident: 10.1016/j.ctarc.2022.100601_bib0015 – volume: 21 start-page: 269 year: 2012 ident: 10.1016/j.ctarc.2022.100601_bib0007 article-title: Benzimidazole: a medicinally important heterocyclic moiety publication-title: Med. Chem. Res. doi: 10.1007/s00044-010-9533-9 – volume: 33 start-page: 1069 year: 1984 ident: 10.1016/j.ctarc.2022.100601_bib0012 article-title: A comparison of the interaction of antihelminth benzimidazoles with tubulin isolated from mammalian tissue and the parasitic nematode Ascaridia galli publication-title: Biochem. Pharm. doi: 10.1016/0006-2952(84)90515-X – volume: 33 start-page: 232 year: 1999 ident: 10.1016/j.ctarc.2022.100601_bib0003 article-title: Benzimidazole derivatives: spectrum of pharmacological activity and toxicological properties (a review) publication-title: Pharm. Chem. J. doi: 10.1007/BF02510042 – volume: 115 start-page: 4824 year: 2009 ident: 10.1016/j.ctarc.2022.100601_bib0014 article-title: The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma publication-title: Blood doi: 10.1182/blood-2009-09-243055 – volume: 68 start-page: 258 year: 2021 ident: 10.1016/j.ctarc.2022.100601_bib0019 article-title: Repurposing of drugs: an attractive pharmacological strategy for cancer therapeutics publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2020.04.006 – volume: 5 start-page: 13 year: 2019 ident: 10.1016/j.ctarc.2022.100601_bib0021 article-title: Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT–tamoxifen hybrid therapy publication-title: npj Breast Cancer doi: 10.1038/s41523-019-0108-8 – volume: 47 start-page: 37 year: 2008 ident: 10.1016/j.ctarc.2022.100601_bib0017 article-title: Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins publication-title: J. Am. Assoc. Lab Anim. Sci. – ident: 10.1016/j.ctarc.2022.100601_bib0018 – volume: 13 year: 2011 ident: 10.1016/j.ctarc.2022.100601_bib0016 article-title: Antiparasitic mebendazole shows survival benefit in two preclinical models of glioblastoma multiforme publication-title: Neuro. Oncol. doi: 10.1093/neuonc/nor077 – ident: 10.1016/j.ctarc.2022.100601_bib0001 doi: 10.5772/intechopen.85229 – volume: 78 start-page: 135 year: 1984 ident: 10.1016/j.ctarc.2022.100601_bib0004 article-title: Benzimidazoles in the treatment of trichuriasis: a review publication-title: Ann. Trop. Med. Parasitol doi: 10.1080/00034983.1984.11811787 – ident: 10.1016/j.ctarc.2022.100601_bib0020 – volume: 5 start-page: 409 year: 2005 ident: 10.1016/j.ctarc.2022.100601_bib0006 article-title: Imidazole and benzimidazole derivatives as chemotherapeutic agents publication-title: Mini. Rev. Med. Chem doi: 10.2174/1389557053544047 – volume: 154 start-page: 11 year: 1997 ident: 10.1016/j.ctarc.2022.100601_bib0011 article-title: Review: modes of Action of Anthelmintic Drugs publication-title: Vet. J doi: 10.1016/S1090-0233(05)80005-X – volume: 7 start-page: 885 year: 1988 ident: 10.1016/j.ctarc.2022.100601_bib0013 article-title: The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles publication-title: Int. J. Paracytol. doi: 10.1016/0020-7519(88)90175-0 – volume: 13 start-page: 223 year: 1990 ident: 10.1016/j.ctarc.2022.100601_bib0002 article-title: The benzimidazole anthelmintic agents—A review publication-title: J. Vet. Pharmacol. Ther. doi: 10.1111/j.1365-2885.1990.tb00773.x |
| SSID | ssj0001821749 |
| Score | 2.1929011 |
| Snippet | •Fenbendazole has similar mechanism of action to some anticancer drugs.•Qualitative and quantitative analysis of formulated fenbendazole indicates some... Highlights•Fenbendazole has similar mechanism of action to some anticancer drugs. •Qualitative and quantitative analysis of formulated fenbendazole indicates... The objective of this study is the assessment of the cytotoxic effect of fenbendazole and its commercially available formulation, which is used for its... |
| SourceID | doaj unpaywall proquest crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 100601 |
| SubjectTerms | Analysis Cancer Cytotoxicity Fenbendazole Hematology, Oncology, and Palliative Medicine |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NS8QwEA3iRS-iqFi_iODRYpukaepNxWUR9KKCt5AmqailFbuL6K93ph_LCqIevJYkLdOXzJtk8oaQwwJIAhcRD73LZShiI0OTyCzMizRNsO608rjfcXUtx3fi8j65nyv1hTlhnTxwZ7hjiwcFDsKQNPUC9aRymRvgzDa3wAtdG61HKpsLptrdFYVUG7kvw6tFLBNskBxqk7vsBGAE0SFjmCYg-5Iwg1tq1fu_eKc59rk0rV7M-5spyzlHNFolKz2DpKfdl6-RBV-tE3XbZ0VSU9G6dNTVDxQYM0UB_ufmhAIcqAWPReuCjjCrC0Lxj7r0G-RudHF7Pg77ogihBc8_CV3hlYmdMMKy2DKHEmtA-zn3nMvYFEpJTIPiygpvPVfGRTwBD5QYo1jqY75JFqu68luEqhRiL17khUg8TF2XJeDwM-bTSJlc8TggbLCJtr1iOBauKPWQGvakW0NqNKTuDBmQo1mnl04w4-fmZ2jsWVNUu24fAAZ0jwH9GwYCIoZfpYcLpbAEwkCPP787_a6bb_pp3OhYN0xH-gZBhBhieLEJCFZA5Kxnz1Q6BvL7Kw8GJGmYx3g4YypfTxvNpEpgQZVKBCScQewvJtz-DxPukGUcsttc2iWLk9ep3wO6Ncn325n1CaimHu0 priority: 102 providerName: Directory of Open Access Journals – databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] dbid: AIKHN link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Rb9QwDI6m28P2gkBsogxQkPZIdG2SpjnexsTpYGIv26S9RWmSTjeq9rTeCcGvx27TYxNoIB4bxU3kOPZnx3EIOa4AJAiZChZ8qZjMrGI2VzNWVkWR47vTOmC848u5WlzJz9f59Q45He_CYFpl1P2DTu-1dWyZRm5OV8vl9IJLpfkMQxgIFPCa1S7YH60nZPfk09ni_FeoRSPuRiCMJAxpxvpDfaaXW4NMgavIOeYMqPg-zGij-lL-D0zVPSi6t2lW9vs3W9f3rNL8KXkS4SQ9GWb8jOyE5jnRlzFFktqGtrWnvr2hAJ8pVuP_2r2nIBvUgfmibUXnmOIFfvmPtg4H5Gr-8fJ0weILCcwBDFgzXwVtMy-tdDxz3GO9NfABhAhCqMxWWivMiRLayeCC0NanIgdzlFureREycUgmTduEF4TqAhwxUZWVzAPsYz_LwfrPeChSbUstsoTwkSfGxfLh-IpFbcY8sVvTM9IgI83AyIS82xKthuoZj3f_gMzedsXS131De3dj4tobhydHHvzSoggSC4yVqrTgRLnSgaPg04TIcanMeLsU9CH8aPn42MWfyEIX93RnMtNxk5rf5C4hakv5QHT_PuTbUZIMbGo8qbFNaDed4UrnoF2VlglhWxH7Fxa-_N_JHJF9_BqiS6_IZH23Ca8Bb63LN3E__QSHdSFk priority: 102 providerName: Elsevier |
| Title | Teaching an old dog new tricks: The case of Fenbendazole |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2468294222000910 https://www.clinicalkey.es/playcontent/1-s2.0-S2468294222000910 https://dx.doi.org/10.1016/j.ctarc.2022.100601 https://www.proquest.com/docview/2685040684 https://doi.org/10.1016/j.ctarc.2022.100601 https://doaj.org/article/c1167d84077e45179b6ba428cbc729d0 |
| UnpaywallVersion | publishedVersion |
| Volume | 32 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2468-2942 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001821749 issn: 2468-2942 databaseCode: DOA dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVESC databaseName: Elsevier E-journals (Freedom Collection) customDbUrl: eissn: 2468-2942 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001821749 issn: 2468-2942 databaseCode: ACRLP dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] customDbUrl: eissn: 2468-2942 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001821749 issn: 2468-2942 databaseCode: AIKHN dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2468-2942 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001821749 issn: 2468-2942 databaseCode: M~E dateStart: 20160101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Rb9MwELZQ-8ATDA1E0FYZaY9kSmzHcXkriKobokJilcaT5dgOgkXJRFIh9uu5S5xqRdMYr5EdK-c733e5u8-EnJQAErhIeOxdIWORGhmbTM7joszzDO-dVh7_d3xay9VGnF9ml4FnG3th9vL3fR2W7WDHIZBjDDP6Enu1pjID4D0h08368-IrXh-H_UNsLtjIK3T3zD3f01P077mgWxDz8ba-Nr9_maq65W2WT4c27rYnKcQik6vTbVec2pu_KBwf-CEH5ElAnXQxqMkz8sjXh0RdhEpKamraVI665hsFlE2RtP-qfUtBhagFL0ebki6xEgzC95um8s_JZvnh4v0qDhcpxBbQQhe70iuTOmGEZallDmnZIFTg3HMuU1MqJbF0iisrvPVcGZfwDLxWZoxiuU_5CzKpm9q_JFTlEK_xsihF5sHc3TwDkDBnPk-UKRRPI8JGEWsbWMbxsotKj-VkP3QvCI2C0IMgIvJmN-l6INm4f_g73LvdUGTI7h-AvHUwOG0xweQgfM1zL5CHrJCFgVjLFhbiCZdERIw7r8cmVDg24UXf7187v2uab4PptzrVLdOJ_oI6iSrJsBkKQFlE5G5mQDcDavn3kq9HxdRg-5jQMbVvtq1mUmVwCEslIhLvNPYhInz1n-OPyKT7ufXHAMC6Ykami7OPq_Ws_4ExC2b4B9PYKa0 |
| linkProvider | Unpaywall |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaq9lAuCASI8DQSR6JN_IqXW6lYbWm7F7ZSb5ZjO9VClKyaXSH49cwkztIKVBBXxxNb43l8Y4_HhLytACRwkfE0-FKlIrcqtVJN07IqConvTuuA-x3nCzW_EJ8u5eUeOR7vwmBaZbT9g03vrXVsmURuTtar1eQzE0qzKW5hIFDAa1YHQvICtPPg6OR0vvi11aIRdyMQRpIUacb6Q32ml9uATEGoyBjmDKj4Pszoo_pS_rdc1Q0oerht1vb7N1vXN7zS7AG5H-EkPRpm_JDsheYR0cuYIkltQ9vaU99eUYDPFKvxf-3eU5AN6sB90baiM0zxgrj8R1uHx-Ri9nF5PE_jCwmpAxiwSX0VtM29sMKx3DGP9dYgBuA8cK5yW2mtMCeKayeCC1xbn3EJ7khaq1kRcv6E7DdtE54SqgsIxHhVVkIG0GM_leD9pywUmbal5nlC2MgT42L5cHzFojZjntgX0zPSICPNwMiEvNsRrYfqGXd3_4DM3nXF0td9Q3t9ZeLaG4cnRx7i0qIIAguMlaq0EES50kGg4LOEiHGpzHi7FOwh_Gh199jFn8hCF3W6M7npmMnMb3KXELWjvCW6fx_yzShJBpQaT2psE9ptZ5jSEqyr0iIh6U7E_oWFz_53Mq_J4Xx5fmbOThanz8k9_DLsNL0g-5vrbXgJ2GtTvoq69RMZ8yRF |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9RAEF_k-uCTH6gYUdmCj6Yk-5U936p4lIJFsAf1admviDYkxeQo7V_vTLI5elJqfQ27WTI7s_ObzMxvCXlXA0jgouB5DE7lorQqt1Itc1dXlcR7p3XE_x1fTtTRWhyfybPEs429MDv5-7EOyw-w4xDIMYYZfYW9WntKAvBekL31ydfD73h9HPYPsaVgM6_Q7TN3fM9I0b_jgm5AzIeb9sJeXdqmueFtVo-nNu5-JCnEIpPzg83gDvz1XxSO9_yQJ-RRQp30cFKTp-RBbJ8RfZoqKaltadcEGrofFFA2RdL-8_4DBRWiHrwc7Wq6wkowCN-vuyY-J-vV59NPR3m6SCH3gBaGPNRR2zIIKzwrPQtIywahAueRc1XaWmuFpVNcexF95NqGgkvwWtJazapY8hdk0XZtfEmoriBe47WrhYxg7mEpASQsWawKbZ3mZUbYLGLjE8s4XnbRmLmc7JcZBWFQEGYSREbebyddTCQbdw__iHu3HYoM2eMDkLdJBmc8JpgChK9VFQXykDnlLMRa3nmIJ0KRETHvvJmbUOHYhBf9vHvt6rZpsU-m35vS9MwU5hvqJKokw2YoAGUZUduZCd1MqOXfS-7PimnA9jGhY9vYbXrDlJZwCCstMpJvNfY-Inz1n-Nfk8XwexPfAAAb3NtkeH8AogEnKg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Teaching+an+old+dog+new+tricks%3A+The+case+of+Fenbendazole&rft.jtitle=Cancer+treatment+and+research+communications&rft.au=Vlachou%2C+Ioanna&rft.au=Parsonidis%2C+Panagiotis&rft.au=Mamagkaki%2C+Alexandra&rft.au=Bouris%2C+Ioannis&rft.date=2022&rft.issn=2468-2942&rft.eissn=2468-2942&rft.volume=32&rft.spage=100601&rft.epage=100601&rft_id=info:doi/10.1016%2Fj.ctarc.2022.100601&rft.externalDBID=ECK1-s2.0-S2468294222000910&rft.externalDocID=1_s2_0_S2468294222000910 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F24682942%2Fcov200h.gif |